By WEforum Editors
For many women, midlife brings an unexpected shift. Cholesterol levels that were once stable begin to rise, sometimes without any clear change in diet or lifestyle. It is tempting to reduce the explanation to one simple line: low estrogen equals high cholesterol. Science suggests a more nuanced picture. Menopause is associated with changes in lipid metabolism, body fat distribution, insulin sensitivity, and cardiovascular risk markers, yet researchers are careful to note that these changes reflect a combination of hormonal shifts, aging, and changes in body composition, rather than a single factor.¹
What changes during menopause
Menopause is not a single event, but a transition that unfolds over several years. During this time, estrogen levels decline, cycles become irregular, and eventually menstruation stops. Alongside these hormonal changes, researchers consistently describe shifts in metabolism, body composition, and cardiovascular risk markers.
Recent reviews emphasize that the menopausal transition is associated with a more atherogenic lipid profile, meaning a pattern more closely linked with cardiovascular risk. This often includes increases in total cholesterol and LDL cholesterol, with more variable changes in triglycerides and HDL.¹
Importantly, these changes may begin before the final menstrual period, suggesting that the transition itself, not just the postmenopausal state, is a meaningful window for metabolic change.¹
Why hormones matter, but are not the whole story
Estrogen is believed to play a role in how the body handles fat and lipoproteins. As estrogen declines, researchers describe changes in lipid metabolism that may contribute to rising LDL and other unfavorable shifts.²
At the same time, menopause is also associated with increased visceral fat, changes in energy expenditure, and a greater tendency toward insulin resistance, all of which can affect cholesterol and triglyceride levels. In other words, hormones matter, but so do the metabolic changes that often travel with menopause.²
That distinction matters. A careful interpretation of the literature does not support the idea that menopause alone causes cholesterol problems in every woman, or that every lipid change in midlife is purely hormonal. The more accurate message is that menopause appears to be a period during which several risk-related processes can converge.¹
What tends to happen to cholesterol levels
Across recent studies and reviews, a fairly consistent pattern emerges. LDL cholesterol often rises during the menopausal transition, and total cholesterol commonly rises as well. Triglycerides may also increase, particularly as abdominal fat and insulin resistance become more prominent.
Part of this appears to be linked to how the body handles LDL. Estrogen plays a role in supporting the liver’s ability to clear LDL particles from the bloodstream. As estrogen levels decline, this process may become less efficient, allowing more LDL to remain in circulation.
At the same time, shifts in body composition and metabolism can further influence how lipids are produced, stored, and transported.
A 2020 study reported significant changes in LDL during the transition and found that total cholesterol and LDL were independently associated with menopause.³ More recent reviews continue to support this overall direction, while also emphasizing that individual responses vary and that not all women experience the same degree of change.¹
HDL is more complicated than the old “good cholesterol” story
HDL has long been described as “good cholesterol” based on its role in helping remove excess cholesterol from the bloodstream and transport it back to the liver. In general, higher HDL levels have been associated with lower cardiovascular risk.
But more recent research suggests that this relationship is not as straightforward as once believed, particularly during and after menopause. Some studies indicate that while HDL levels may remain stable or even increase, the function of HDL may change.⁴
HDL is not a single, uniform particle. It exists in different sizes and subtypes, and its protective role depends not just on how much is present, but on how well it performs key functions, such as cholesterol transport and interacting with inflammatory processes.
During the menopausal transition, shifts in hormones, body fat distribution, and metabolism may influence HDL characteristics. As a result, a higher HDL number does not always carry the same meaning it might have earlier in life.⁴
This does not mean HDL becomes unimportant. It means it should be interpreted in context. Rather than focusing on HDL alone, many clinicians now look at the broader lipid profilepattern, including LDL cholesterol, non-HDL cholesterol, triglycerides, and in some cases ApoB or lipoprotein(a), to better understand overall cardiovascular risk.¹
Why body fat redistribution matters
Another theme that comes through clearly in the recent literature is that menopause is not only about ovarian hormone decline. It is also about where fat is stored and how the body uses energy. Reviews describe a tendency toward more visceral or abdominal fat, altered lipid handling, and greater insulin resistance after menopause.²
This shift helps explain why many women feel their bodies change quickly during this stage of life, even if their diet and exercise habits have not changed. At the same time, the literature indicates that lifestyle factors continues to play an important role, particularly physical activity, body composition, and dietary patterns.¹
Does hormone therapy help with cholesterol, and what are its limits?
The answer is nuanced.
Recent reviews and meta-analyses suggest that menopausal hormone therapy can improve some lipid measures, particularly by lowering total cholesterol and LDL cholesterol. However, the effect depends on the formulation and route of administration.⁵
Oral estrogen tends to have a more pronounced effect on lipid levels, while transdermal estrogen generally has a more limited impact on lipids and other liver-mediated pathways.⁶
At the same time, improvements in cholesterol markers do not mean hormone therapy should be presented as a universal cardiovascular prevention strategy. The cardiovascular literature remains more cautious. Hormone therapy may be appropriate for symptom management in selected women, and lipid effects can be part of the discussion, but treatment decisions depend on age, timing, personal risk factors, and clinical context.⁷
What women may want to monitor
If cholesterol changes during menopause are common, it is reasonable for women and their clinicians to pay closer attention to lipid patterns during this stage of life.
Standard lipid panels remain useful, but depending on the clinical picture, some women may also discuss broader markers. The key point is not to overinterpret every midlife lab shift, but not to dismiss them.¹
Where lifestyle still matters
The existence of hormonal and metabolic changes does not make lifestyle irrelevant. In fact, recent meta-analyses suggest that exercise can improve several cardiometabolic measures in postmenopausal women.
A 2023 systematic review and meta-analysis found that resistance training decreased total cholesterol, LDL cholesterol, and triglycerides.⁸ Another review reported improvements in vascular function and reductions in lipid markers with exercise interventions.⁹
These findings reinforce that while menopause-related changes are real, they are not entirely fixed, and lifestyle remains a meaningful part of the equation.
The bottom line
The science supports a clear but careful conclusion. Menopause is often associated with changes in cholesterol and lipid metabolism, particularly rising LDL levels and broader cardiometabolic shifts, but the process is not explained solely by estrogen decline. Aging, visceral fat redistribution, insulin resistance, and overall metabolic change are part of the picture.¹
For women in midlife, that message may be more useful than a simplified explanation. A cholesterol shift during menopause is neither imaginary nor automatically alarming. It is a meaningful physiological signal, one that deserves context, thoughtful follow-up, and a more informed conversation than many women have historically been given.¹
Disclaimer
This article is for informational purposes only and is based on current scientific literature. It is not intended to provide medical advice, diagnosis, or treatment. Individual health decisions should be made in consultation with a qualified healthcare provider, taking into account personal medical history, risk factors, and clinical context.
References (PubMed Indexed)
- Cabre HE, et al. Precision Nutrition for Management of Cardiovascular Alterations During Menopause. Nutrients. 2024.
- Ko SH, Jung Y. Energy Metabolism Changes and Dysregulated Lipid Metabolism in Postmenopausal Women. Nutrients. 2021;13(12):4556.
- Inaraja V, et al. Lipid profile changes during the menopausal transition. 2020. (slightly older than 5 years)
- El Khoudary SR, et al. HDL subclasses, lipid particle size, and menopause transition timing. 2021.
- Zhang YL, et al. Meta-analysis of hormone therapy effects on lipid profiles. 2024.
- Goldštajn MŠ, et al. Effects of transdermal versus oral hormone therapy. 2023.
- Shufelt CL, et al. Menopausal Hormone Therapy and Cardiovascular Disease. 2021.
- He M, et al. Resistance training and lipid profile in postmenopausal women. 2023.
- Xin C, et al. Exercise effects on vascular function and lipids in postmenopausal women. 2022.
Photo credit: Christoph Burgstedt
